Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The prognostic impact of TP53 mutation in MPNs

Raajit Rampal • 26 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the prognostic impact of TP53 mutation in myeloproliferative neoplasms (MPNs). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Raajit Rampal

Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 24 Nov 2022
1:00
How genomic testing has influenced treatment approaches and clinical trial design in MPNs
Raajit Rampal • 26 Aug 2022
1:05
Venetoclax-based combinations in patients with accelerated and blast-phase MPNs
Raajit Rampal • 26 Aug 2022
0:47
Challenges in treating PV and optimal management strategies
Raajit Rampal • 26 Aug 2022

Related Videos

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
2:45
The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals